These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely
Nov 25
U.S. Biotech Industry Analysis
UpdatedNov 28, 2022
DataAggregated Company Financials
Companies638
- 7D0.4%
- 3M12.5%
- 1Y-14.4%
- YTD-11.2%
Over the last 7 days, the Biotech industry has remained flat, although notably BeiGene declined by 14%. Unfortunately though, the industry is down 14% over the past 12 months. Earnings are forecast to grow by 9.4% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 28 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.6x | 845.5x | 5.6x |
| Wed, 26 Oct 2022 | US$1.1t | US$206.5b | US$5.5b | 16.4x | 198.7x | 5.3x |
| Fri, 23 Sep 2022 | US$1.0t | US$206.2b | US$5.7b | 14.1x | 180.9x | 5x |
| Sun, 21 Aug 2022 | US$1.1t | US$206.4b | US$7.3b | 16x | 147.7x | 5.2x |
| Tue, 19 Jul 2022 | US$1.1t | US$211.3b | US$10.6b | 17.2x | 102.8x | 5.2x |
| Thu, 16 Jun 2022 | US$937.2b | US$212.0b | US$10.9b | 15.1x | 86.2x | 4.4x |
| Sat, 14 May 2022 | US$993.8b | US$212.0b | US$10.6b | 14.4x | 93.7x | 4.7x |
| Mon, 11 Apr 2022 | US$1.3t | US$226.8b | US$14.3b | 18.8x | 92.1x | 5.8x |
| Wed, 09 Mar 2022 | US$1.2t | US$221.8b | US$10.6b | 18.7x | 112.2x | 5.4x |
| Fri, 04 Feb 2022 | US$1.2t | US$213.5b | US$5.5b | 21.7x | 225.8x | 5.8x |
| Sun, 02 Jan 2022 | US$1.4t | US$212.1b | US$2.8b | 25.5x | 509.6x | 6.7x |
| Tue, 30 Nov 2021 | US$1.5t | US$211.9b | US$3.1b | 24.9x | 470x | 7x |
| Thu, 28 Oct 2021 | US$1.5t | US$195.7b | -US$3,085,811,125.00 | 24.1x | -478.2x | 7.5x |
| Sat, 25 Sep 2021 | US$1.6t | US$196.4b | -US$2,406,343,544.00 | 24.9x | -657.2x | 8.1x |
| Mon, 23 Aug 2021 | US$1.6t | US$197.0b | -US$1,662,914,785.58 | 22.3x | -956x | 8.1x |
| Sat, 10 Jul 2021 | US$1.5t | US$196.9b | -US$825,939,314.84 | 25.2x | -1810.8x | 7.6x |
| Fri, 02 Apr 2021 | US$1.4t | US$174.8b | -US$10,804,700,199.55 | 20.3x | -125.6x | 7.8x |
| Mon, 04 Jan 2021 | US$1.3t | US$162.7b | -US$10,861,442,801.14 | 19.2x | -121.1x | 8.1x |
| Thu, 08 Oct 2020 | US$1.2t | US$150.3b | -US$4,331,812,814.88 | 20.2x | -265.6x | 7.7x |
| Wed, 01 Jul 2020 | US$1.1t | US$138.4b | -US$4,989,424,690.29 | 20.9x | -226.8x | 8.2x |
| Sat, 04 Apr 2020 | US$726.8b | US$100.1b | -US$4,690,733,128.42 | 15.6x | -154.9x | 7.3x |
| Tue, 07 Jan 2020 | US$764.7b | US$98.3b | -US$448,688,283.23 | 14.7x | -1704.4x | 7.8x |
Price to Earnings Ratio
-269.2x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 846x which is higher than its 3-year average PE of -227x.
- The 3-year average PS ratio of 7.1x is higher than the industry's current PS ratio of 5.6x.
Past Earnings Growth
- Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 28% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.26% | |
| Healthcare | 1.63% | |
| Biotech | 0.44% | |
| Biotech | 0.44% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$159.62 | 3.0% +US$8.2b | 37.0% | PE21.1x | |
| GILD Gilead Sciences | US$86.26 | 3.2% +US$3.3b | 22.8% | PE32.5x | |
| BMRN BioMarin Pharmaceutical | US$96.92 | 9.8% +US$1.6b | 10.7% | PE214.7x | |
| MRTX Mirati Therapeutics | US$98.62 | 28.5% +US$1.3b | -27.9% | PS481.3x | |
| IMGO Imago BioSciences | US$35.66 | 104.9% +US$618.3m | 51.7% | PB7x |
